Saundra Maass-Robinson
Psychiatry · Atlanta, GANPI 1154442598
Payments from drug & device makers
What this record shows
Merck accounts for 65.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,671 and has fallen 98.1% since, to $31 in 2024.
Across 51 payments — averaging $50.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Lundbeck LLC$406
- AbbVie$215
- Otsuka America Pharmaceutical, Inc.$106
- Bausch Health US, LLC$55
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48
- plus $50 from 2 others
Across 1,514 payments — averaging $7321.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.1M
- E.r. Squibb & Sons, L.L.C.$2.3M
- Teva Pharmaceuticals USA, Inc.$1.9M
- Sumitomo Pharma America, Inc.$973K
- Sunovion Pharmaceuticals Inc.$917K
- Boehringer Ingelheim International GmbH$408K
- plus $1.5M from 10 others
What the payments were for
- Travel & lodging$1,41355%
- Food & beverage$1,13745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $1,671 |
| Lundbeck LLC | 26 | $406 |
| AbbVie(2 entities) | 9 | $215 |
| Otsuka America Pharmaceutical, Inc. | 1 | $106 |
| Bausch Health US, LLC | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,550 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 11 | $121 |
| Fluoxetine Hcl | 13 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Atlanta
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Ray HorwitzAtlanta$64K
- Boadie DunlopAtlanta$61K
- Zohaib HaqueAtlanta$49K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.